Efficacy and tolerability of levetiracetam in central post-stroke pain - a randomised, double blind, placebo controlled, cross-over study

Submission date	Recruitment status No longer recruiting	Prospectively registered		
11/05/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
07/06/2005	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
23/02/2023	Circulatory System			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Gerhard Jan Jungehülsing

Contact details

Klinik für Neurologie Charité Campus Mitte Schumannstr. 20/21 Berlin Germany 10117 +49 30 450 560 145 jan.junge-huelsing@charite.de

Additional identifiers

Protocol serial number N/A

Study information

Scientific Title

Efficacy and tolerability of levetiracetam in central post-stroke pain - a randomised, double blind, placebo controlled, cross-over study

Acronym

LESS

Study objectives

Levetiracetam has a positive pain relief effect in patients with central post stroke pain and is well tolerated.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Central poststroke pain (CPSP)

Interventions

The study is based on a cross over design. Each randomised patient will receive 8 weeks of Levetiracetam and 8 weeks of placebo in blinded order. The medication periods consist of a 4 week titration phase starting with 1000 mg/day (14 days) to 2000 mg/day (14 days) and followed by 4 weeks of a constant dose of 3000 mg/day.

Pain diary based on NRS, lab test, cerebral magnetic resonance imaging (MRI), neurological examination including extended sensibility and sensory testing, questionnaires, drug administration.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Levetiracetam

Primary outcome(s)

Primary endpoint is a reduction of two points in the median pain intensity on a scale 0 (no pain) to ten (maximum pain) assessed by the patient during the last week of treatment with 3000 mg levetiracetam or placebo compared to the median pain intensity assessed in the second pretreatment baseline week.

Key secondary outcome(s))

Secondary endpoints are the median pain scale during the last week of treatment with 1000 mg and 2000 mg levetiracetam or placebo. Further secondary endpoints are the results of the clinical sensory and pain assessment and the results of the NRS (Numeric Rating Scale), Beck Depression Inventary, the SF36 (Short Form-36 Health Survey (Quality of Life) as well as the PSQI (Pittsburgh Sleep Quality Index).

Completion date

31/12/2005

Eligibility

Key inclusion criteria

- 1. Age >18 years
- 2. Central Post Stroke Pain >3 months
- 3. Previous ischaemic or haemorrhagic stroke > 3 months
- 4. Pain intensity >4 on numeric rating scale (NRS)
- 5. Rankin Score <2

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

ΔII

Total final enrolment

42

Key exclusion criteria

- 1. Dementia or other severe cognitive impairment
- 2. Diabetic neuropathy
- 3. Epilepsy
- 4. Severe pain other than central poststroke pain
- 5. Malignant disease
- 6. Recent myocardial infarction
- 7. Severe heart insufficiency
- 8. Severe liver or renal failiure
- 9. Severe hematological disease
- 10. Prior treatment with or known allergy to levetiracetam
- 11. Positive history for alcohol or for drug abuse

- 12. Pregnancy or lactation
- 13. Participation in a clinical study within two months of screening

Date of first enrolment

01/10/2004

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

Germany

Study participating centre Klinik für Neurologie Berlin

Germany 10117

Sponsor information

Organisation

Individual Sponsor (Germany)

Funder(s)

Funder type

Industry

Funder Name

Charité - University Medicine Berlin (Charité - Univeritätsmedizin Berlin) (Germany)

Funder Name

Berlin Neuroimaging Centre (Germany)

Funder Name

UCB Pharma Belgium (Belgium)

Funder Name

UCB GmbH Kerpen (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/02/2013	23/02/2023	Yes	No